SCHEMBL9892928

SCHEMBL9892928

CC(C)(C)OC(=O)N1CC[C@H]1C(=O)Nc1nc(-c2ccccc2)cs1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.56
ALDH1A1 P00352 3/20 0.56
LMNA P02545 3/20 0.56
RAB9A P51151 2/20 0.56
KCNQ1 P51787 3/20 0.55
CNR2 P34972 1/20 0.55
MAPT P10636 2/20 0.54
USP2 O75604 2/20 0.54
HSD17B10 Q99714 1/20 0.54
HTT P42858 3/20 0.50
USP30 Q70CQ3 3/20 0.50
UCHL1 P09936 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
NPC1 O15118 2/20 0.50
ELOVL1 Q9BW60 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13257794 0.93 KCNQ1 (0.65) SMN1; SMN2ALDH1A1LMNARAB9AKCNQ1
SCHEMBL16237618 0.93 KCNQ1 (0.65) SMN1; SMN2ALDH1A1LMNARAB9AKCNQ1
SCHEMBL31197984 0.89 USP30 (0.62) SMN1; SMN2ALDH1A1LMNARAB9AKCNQ1
SCHEMBL31198019 0.88 RAB9A (0.52) SMN1; SMN2ALDH1A1LMNARAB9AKCNQ1
SCHEMBL31198022 0.88 RAB9A (0.52) SMN1; SMN2ALDH1A1LMNARAB9AKCNQ1
SCHEMBL31198062 0.88 RAB9A (0.52) SMN1; SMN2ALDH1A1LMNARAB9AKCNQ1
SCHEMBL31197947 0.88 RAB9A (0.52) SMN1; SMN2ALDH1A1LMNARAB9AKCNQ1
SCHEMBL31197951 0.87 RAB9A (0.52) SMN1; SMN2ALDH1A1LMNARAB9AKCNQ1
SCHEMBL31197974 0.87 RAB9A (0.52) SMN1; SMN2ALDH1A1LMNARAB9AKCNQ1
SCHEMBL31198027 0.87 RAB9A (0.52) SMN1; SMN2ALDH1A1LMNARAB9AKCNQ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443107-B1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2018-08-08 EP disclosed
US-8383615-B2 Azetidine 2-carboxamide derivatives which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-26 US disclosed
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-07 US disclosed
WO-2010147791-A1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 SMN1; SMN2 4282/4885ALDH1A1 1724/4885LMNA 4544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.